The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So the focus has been using ketone metabolic therapy as an adivant for like mafet institute carti therapy for lymphoma. So they have that project but we just working on some grants for ketone metabolic therapy and it's strictly their focus on beta hydroxybutyrate because that correlates with the adaptive immune response that will augment uh checkpoint inhibitors specifically PD1 inhibitors and CTLA uh for uh checkpoint inhibitors.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.